N/A N=302 Retrospective Chart Review of enVista Toric 0.9D Intraocular Lenses
Corneal Astigmatism
Primary: Mean Reduction in Cylindrical Power of the Eye — 0.432; 0.071 Diopters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
COVID-19 · Influenza
Primary: Positive Percent Agreement — 52 percent of nasal swabs
Phase 3 N=780 Intermittent Preventive Treatment of Malaria in Schoolchildren
Malaria · Intermittent Preventive Treatment
Primary: Risk of Parasitaemia (Unadjusted by Genotyping) — 23; 87; 164; 147 Participants
Phase 2 N=20 Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria
Cholinergic Urticaria
Primary: Change From Baseline in Post-provocation Urticaria Activity Score (UASprovo) — -1.1; -0.5 scores on a scale — p=0.277
N/A N=54 RhD+ Blood Transfusion to Asian-type DEL Recipients
Blood Transfusion · Rhesus Isoimmunisation Due to Anti-D · Blood Group Antigen Abnormality
Primary: Occurrence of Alloanti-D Immunization in Asian-type DEL Recipients Transfused With RhD+ RBCs — 42; 12 Participants — p=< 0.001
Phase 1 N=20 Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
Healthy
Primary: Ratio of Cmax of BI 409306 in CSF Compared to Plasma — 0.267; 0.244; 0.294; 0.335 Ratio — p=1.0000
Phase 1 N=17 A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Frequency of Dose-limiting Toxicity at Escalating Dose Levels of CTT1403 — 0; 0; 0; 0 Participants
N/A N=136 Ingenio Device Algorithm Study
Sinus Node Disease · AV Block · Heart Failure
Primary: Accuracy of Commanded Right Atrial Automatic Threshold (RAAT) — 100 percentage of accurate RAAT tests
N/A N=59 Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic
Bulimia Nervosa · Bulimia; Atypical · Binge Eating
Primary: Binge Eating Frequency Assessed by the Eating Disorder Examination — 25.10; 25.27; 9.19; 13.07 Binge eating episodes
Phase 4 N=100 Sugammadex Titration in Cardiac Surgery Patients
Coronary Artery Disease · Valvular Heart Disease · Aorta Disease
Primary: Total Dose of Sugammadex Required to Produce a Train-of-four Ratio of >0.9, Categorized as Greater Than or Less Than the Manufacturers Recommended Dose Based on the…
Phase 1 N=24 STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 23.56; 31.37; 51.82; 78.73 nanogram per milliliter (ng/mL)
N/A N=325 Preventing the Spread of Infection in Nursing Homes
Staphylococcus Aureus
Primary: Rates of Staphylococcus Aureus Acquisition: Percentage of Short Stay Participants Who Acquired MRSA or MSSA (or Both) During the Study Period — 17; 8 Participants
Phase 2 N=162 Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
Chronic Kidney Diseases · Hypertension
Primary: Systolic Blood Pressure — 155.8; 154.3; 155.7; 150.4 mmHg
Phase 3 N=288 L-PZQ ODT in Schistosoma Infected Children
Schistosomiasis
Primary: Cohort 1a and Cohort 1b: Number of Participants With Clinical Cure Determined by Kato-Katz Method — 86; 39 Participants
Phase 3 N=51 Perioperative Patient Skin Antiseptic Preparation Evaluation
Surgical Site Infection
Primary: Surgical Site Infection Occurrence — 0; 1 Participants